Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, et al.
N Engl J Med. 2014 Jan 23; 370(4):322-33. PMID: 24450891. Abstract
Top50 Topics: 
Biomarkers, Clinical Trials